The AI system can detect a larger number of high-risk patients across France, Germany, Italy, Spain, and the UK by 2030.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology ...

DarioHealth, a digital chronic condition management platform, announced the integration of Twill's condition-specific communities and peer groups with customized navigation expertise into its ...

Utilizing Owkin’s expansive data network and cutting-edge AI, this solution optimizes pre-screening for gBRCA mutations in breast cancer directly from digitized H&E pathology slides The solution ...

Thomas Clozel, MD, CEO of Owkin, said: "We are excited to collaborate with AstraZeneca to bring the benefits of AI to BRCA testing with the gBRCA Pre-Screen solution. During Breast Cancer ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca ...